RJFSA
FATE icon

Raymond James Financial Services Advisors’s Fate Therapeutics FATE Stock Holding History

Raymond James Financial Services Advisors’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-22,039
Closed -$162K – 3448
2024
Q1 		$162K Buy
+22,039
New +$136K ﹤0.01% 3149
2021
Q2 		– Sell
-3,983
Closed -$328K – 3333
2021
Q1 		$328K Buy
3,983
+43
+1% +$4.12K ﹤0.01% 2565
2020
Q4 		$358K Buy
+3,940
New +$245K ﹤0.01% 2350

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Raymond James Financial Services Advisors's FATE Position: Q2 2024 in Review

Raymond James Financial Services Advisors sold out of Fate Therapeutics (FATE) in Q2 2024, closing a stake of 22,039 shares — an estimated $162K sold.

Raymond James Financial Services Advisors first reported a position in FATE in Q4 2020 and held it in 3 quarters. The position peaked at $358K in Q4 2020. 182 funds tracked by Wall St. Rank hold FATE as of Q2 2024.

  • Raymond James Financial Services Advisors reported no remaining Fate Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Raymond James Financial Services Advisors sold 22,039 Fate Therapeutics shares in Q2 2024, an estimated $162K.
  • Raymond James Financial Services Advisors first reported a position in Fate Therapeutics in Q4 2020 and held it in 3 quarters.
  • Raymond James Financial Services Advisors's Fate Therapeutics position peaked at $358K in Q4 2020.
  • 182 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2024.

Based on Raymond James Financial Services Advisors's 13F filing for Q2 2024, filed 19 Jul 2024.